Program
milsaperidone
Also written as “VHX-896 and iloperidone”, “Iloperidone and VHX-896” and “Milsaperidone”.
Its studies are mostly in Depressive Disorder, Major · Schizophrenia, led by Vanda Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vanda Pharmaceuticals | 41 open or running | phase 3since Feb 11, 2025 | Jul 9, 2021 | Mar 2028phase 3 · NCT06830044 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 9, 2021First study: phase 1 study in HealthyFirst studyNCT04969211 · 25 enrolled · United States
- Jul 2, 2024Phase 1 study in SchizophreniaNCT06494397 · 26 enrolled · United States
- Jan 27, 2025Phase 1 study in HealthyNCT06803290 · 24 enrolled · United States
- Feb 11, 2025Phase 3 study in Depressive Disorder, MajorNCT06830044 · 500 planned · United States, Bulgaria, Czechia and more
Ahead
- Mar 2028Primary completion: phase 3 study in Depressive Disorder, MajorNCT06830044
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06830044Depressive Disorder, Major · United States, Bulgaria, Czechia and more | 3 | Recruiting | Mar 2028 | 500 |
| NCT06803290Healthy · United States | 1 | Completed | Dec 27, 2022 | 24 |
| NCT06494397Schizophrenia · United States | 1 | Completed | Oct 24, 2024 | 26 |
| NCT04969211Healthy · United States | 1 | Completed | Oct 13, 2021 | 25 |
How it is read
Names in the registry
- “VHX-896 and iloperidone”, 2 entries
- “Iloperidone and VHX-896”, 2 entries
- “Milsaperidone”, 1 entry
- “VHX-896”, 1 entry
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 1 study
- Schizophrenia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.